B

BridgeBio

341 employees

BridgeBio Pharma focuses on the development and commercialization of precision medicines for various genetic diseases and cancers.

Investor insights

Sectors invested in

Biotechnology5
Therapeutics4
Biopharma3
Health Care3
Cardiomyopathy2
Medical2
heart failure2
drug discovery2
therapeutics2
R&D2
precision medicine2
cardiovascular disease2
biotechnology2
Genetic Heart Disease2
drug development2
Pharmaceutical1
Medical Device1
Basal Cell Carcinoma1
Gorlin Syndrome1
Hedgehog Signaling1

Funding rounds participated in

$46M sweet spot round size

Most of their 5 investments are in rounds between $10M and $64M

Basic info

Industry

biotechnology research

Sectors

Biotechnology
Health Care
Medical
Pharmaceutical
Life Science

Date founded

2014

Investments made

E

Eidos Therapeutics raised $64M on April 5, 2018

Investors: Aisling Capital, Viking Global Investors, RA Capital Management, L.P., Perceptive Advisors and BridgeBio

Q

QED Therapeutics raised $65M on January 30, 2018

Investors: BridgeBio

P

PellePharm raised $20M on August 1, 2017

Investors: BridgeBio

M

MyoKardia raised $46M on April 30, 2015

Investors: Casdin Capital, LLC, Cowen Inc. and BridgeBio

M

MyoKardia raised $10M on August 22, 2014

Investors: Third Rock Ventures, Cowen Inc., Casdin Capital, LLC and BridgeBio

Funding rounds raised

Total raised

$299M

from 14 investors over 14 rounds

B

BridgeBio raised $250M on September 22, 2023

Investors: Qatar Investment Authority

B

BridgeBio raised $299M on January 23, 2019

Investors: Aisling Capital, Hercules Capital, Inc., Perceptive Advisors, Viking Global Investors, KKR & Co. Inc. and Cormorant Capital

B

BridgeBio raised $135M on September 13, 2017

Investors: Aisling Capital, Perceptive Advisors, Viking Global Investors, Cormorant Capital and KKR & Co. Inc.

B

BridgeBio raised $33M on May 1, 2017

Investors: KKR & Co. Inc.

B

BridgeBio raised $6.9M on March 1, 2016

Investors: KKR & Co. Inc.

FAQ